Source comparison
Mechanism of Action: Direct vs Upstream Intervention
IGF-1 LR3 functions as a long-acting IGF-1 receptor agonist. The 'LR3' designation refers to a 13-amino-acid N-terminal extension and a glutamic acid substitution at position 3, which together reduce binding affinity for IGF-binding proteins (IGFBPs) by approx
This comparison does not assign a generated winner or score.
- IGF-1 LR3 functions as a long-acting IGF-1 receptor agonist. The 'LR3' designation refers to a 13-amino-acid N-terminal extension and a glutamic acid substitution at position 3, which together reduce binding affinity for IGF-binding proteins (IGFBPs) by approximately 100-fold. Endogenous IGF-1 circulates bound to IGFBP-3 in a ternary complex with the acid-labile subunit, restricting bioavailability to less than 1% of total circulating IGF-1. IGF-1 LR3's structural modifications allow it to remain unbound and biologically active for 20–30 hours post-injection, delivering sustained systemic exposure to IGF-1 receptor signaling.
- The anabolic effects are dose-dependent and tissue-nonspecific: IGF-1 LR3 activates PI3K/Akt and MAPK/ERK pathways in myocytes, adipocytes, chondrocytes, and hepatocytes simultaneously. Research models using IGF-1 LR3 at 40–80 mcg/day demonstrate measurable increases in protein synthesis rates within 48–72 hours, alongside enhanced glucose uptake and reduced proteolysis. The compound doesn't discriminate between muscle and connective tissue. Receptor activation occurs wherever IGF-1 receptors are expressed.
- Tesamorelin + Ipamorelin blends operate at a different level of the endocrine cascade. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with 44 amino acids, identical to the first 29 residues of native GHRH but stabilized against enzymatic degradation. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering calcium-mediated exocytosis of stored growth hormone. Mimicking the physiological GH pulse that occurs during deep sleep and post-exercise recovery. Ipamorelin, a pentapeptide ghrelin mimetic, binds to ghrelin receptors (GHS-R1a) on the same somatotrophs, synergizing with Tesamorelin to amplify GH release without stimulating ACTH or cortisol secretion the way earlier secretagogues like GHRP-6 did.
- The resulting growth hormone pulse elevation drives hepatic IGF-1 production over the following 6–12 hours. Not immediate systemic IGF-1 receptor activation. Growth hormone itself exerts direct lipolytic effects via hormone-sensitive lipase activation in adipocytes before converting to IGF-1. Tesamorelin gained FDA approval in 2010 specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy, with clinical trials showing 15–18% reductions in visceral fat after 26 weeks at 2mg daily dosing. Ipamorelin's addition to research protocols enhances GH pulse amplitude without the appetite stimulation or blood glucose dysregulation seen with earlier ghrelin analogs.